Risk and outcomes of COVID‐19 in patients with multiple sclerosis

• DOI: 10.1111/ene.14990
• Publication Date: 2021-06-21T09:23:20Z
• Authors: Irene Moreno‐Torres; Virginia Meca Lal...; Lucienne Costa‐Fr...; Celia Oreja‐Guevara; Clara Aguirre; Elda María Alba S...; Mayra Gómez Moreno; Laura Borrega Canelo; Julia Sabín Muñoz; Yolanda Aladro; Alba Cárcamo; Elena Rodríguez G...; Juan Pablo Cuello; Enric Monreal; Susana Sainz de l...; Fernando Pérez Parra; Francisco Valenzu...; Carlos López de S...; Ignacio Casanova; Maria Luisa Martí...; Rosario Blasco; Aida Orviz García; Luisa María Villa...; Guillermo Fernánd...; Víctor Elvira; Carmen Santiuste; Mercedes Espiño; José Manuel Garcí...
• Keywords: Rate ratio

Limited information is available on incidence and outcomes of COVID-19 in patients with multiple sclerosis (MS). This study investigated the risks SARS-CoV-2 infection COVID-19-related MS, compared these general population.A regional registry was created to collect data incidence, hospitalization rates, intensive care unit admission, death MS COVID-19. National government seroprevalence were used for comparison. The conducted at 14 specialist treatment centers Madrid, Spain, between February May 2020.Two-hundred nineteen included registry, 51 whom hospitalized mean age ± standard deviation 45.3 12.4 years, duration 11.9 8.9 years. rate lower than population (adjusted ratio = 0.78, 95% confidence interval [CI] 0.70-0.80), but rates higher (relative risk 5.03, CI 3.76-6.62). Disease severity generally low, only one admission an five deaths. Males had females. No association found use any disease-modifying risk.Patients do not appear have greater or severe population. decision start continue should be based a careful risk-benefit assessment.